AU5125298A - Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies - Google Patents

Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies

Info

Publication number
AU5125298A
AU5125298A AU51252/98A AU5125298A AU5125298A AU 5125298 A AU5125298 A AU 5125298A AU 51252/98 A AU51252/98 A AU 51252/98A AU 5125298 A AU5125298 A AU 5125298A AU 5125298 A AU5125298 A AU 5125298A
Authority
AU
Australia
Prior art keywords
dyslipoproteinemia
treatment
recombinant viruses
related pathologies
viruses useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU51252/98A
Other versions
AU721654B2 (en
Inventor
Patrick Benoit
Nicolas Duverger
Didier Rouy
Sandrine Seguret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU5125298A publication Critical patent/AU5125298A/en
Application granted granted Critical
Publication of AU721654B2 publication Critical patent/AU721654B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU51252/98A 1996-11-15 1997-11-13 Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies Ceased AU721654B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR96/13969 1996-11-15
FR9613969A FR2755975B1 (en) 1996-11-15 1996-11-15 BICISTRONIC RECOMBINANT VIRUSES USEFUL FOR THE TREATMENT OF DYSLIPOPROTEINEMIA-RELATED CONDITIONS
PCT/FR1997/002043 WO1998022606A1 (en) 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Publications (2)

Publication Number Publication Date
AU5125298A true AU5125298A (en) 1998-06-10
AU721654B2 AU721654B2 (en) 2000-07-13

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51252/98A Ceased AU721654B2 (en) 1996-11-15 1997-11-13 Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies

Country Status (14)

Country Link
EP (1) EP0941355A1 (en)
JP (1) JP2001506488A (en)
KR (1) KR20000053320A (en)
AU (1) AU721654B2 (en)
BR (1) BR9712957A (en)
CA (1) CA2271437A1 (en)
CZ (1) CZ170399A3 (en)
FR (1) FR2755975B1 (en)
HU (1) HUP9904500A3 (en)
IL (1) IL129823A0 (en)
NO (1) NO992260D0 (en)
SK (1) SK63499A3 (en)
WO (1) WO1998022606A1 (en)
ZA (1) ZA9710271B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064392A2 (en) * 1998-03-16 2001-01-03 Introgen Therapeutics, Inc. Multigene vectors
WO2001011063A2 (en) * 1999-08-10 2001-02-15 Develogen Ag Für Entwicklungsbiologische Forschung Gene transfer combination vectors, method for the production and utilization thereof
FR2799472B1 (en) * 1999-10-07 2004-07-16 Aventis Pharma Sa PREPARATION OF RECOMBINANT ADENOVIRUSES AND ADENOVIRAL BANKS
AU2001247648B2 (en) * 2000-03-24 2006-03-30 Cold Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7179659B2 (en) 2001-04-02 2007-02-20 Agilent Technologies, Inc. Sensor surfaces for detecting analytes and methods of use
ES2734221T3 (en) * 2011-08-08 2019-12-04 Allergan Pharmaceuticals Int Ltd Method for dissolution test of solid compositions containing digestive enzymes
JP7316711B2 (en) * 2019-08-19 2023-07-28 ナンジン・ノベル・バイオテクノロジー・カンパニー・リミテッド A replicating oncolytic adenovirus that regulates lipid metabolism and its application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2114416C (en) * 1991-08-07 1998-07-07 W. French Anderson Retroviral vectors containing internal ribosome entry sites
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (en) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Recombinant viruses and their use in gene therapy.
FR2722208B1 (en) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
EP0787200B1 (en) * 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
FR2731710B1 (en) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa RECOMBINANT VIRUSES EXPRESSING LECITHIN CHOLESTEROL ACYLTRANSFERASE AND USES IN GENE THERAPY

Also Published As

Publication number Publication date
FR2755975B1 (en) 1999-05-07
AU721654B2 (en) 2000-07-13
CZ170399A3 (en) 1999-08-11
FR2755975A1 (en) 1998-05-22
JP2001506488A (en) 2001-05-22
EP0941355A1 (en) 1999-09-15
BR9712957A (en) 2000-02-01
KR20000053320A (en) 2000-08-25
WO1998022606A1 (en) 1998-05-28
CA2271437A1 (en) 1998-05-28
NO992260L (en) 1999-05-10
ZA9710271B (en) 1998-08-21
NO992260D0 (en) 1999-05-10
HUP9904500A3 (en) 2002-01-28
IL129823A0 (en) 2000-02-29
SK63499A3 (en) 2000-05-16
HUP9904500A2 (en) 2000-05-28

Similar Documents

Publication Publication Date Title
AU3441197A (en) 3-ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes
IL128736A0 (en) Methods using cre-lox for production of recombinant adeno-associated viruses
AU9397098A (en) Methods and cell line useful for production of recombinant adeno-associated viruses
AU2228297A (en) Use of isoniazid for the treatment of hyperlipoproteinemia
AU3552399A (en) Recombinant poliovirus for the treatment of cancer
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU5432798A (en) Materials and procedures for the purification of cells
AU1697197A (en) Immunoconjugate for the treatment of aids
AU5125298A (en) Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies
AUPO026596A0 (en) Viral peptide
AU2205099A (en) Chimeric proteins for the treatment of diabetes
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU2577495A (en) Cephalosporin compounds and processes for the preparation thereof
AU3783097A (en) Process for the preparation of hexanitrohexaazaisowurtzitanes
AU6492496A (en) Biomedical electrode
HUP0000807A2 (en) Process for the preparation of optically active n-benzyl-3-pyrrolidinol
AU1363595A (en) Improved kiln
AU4582597A (en) Therapeutic proteins
GB9726223D0 (en) The treatment of materials
AU3934395A (en) Enzyme stabilization
AU1979397A (en) Peptidomimetics for the treatment of hiv infection
AU1207497A (en) Process for the preparation of para-fluorophenol
AU1991095A (en) Activating virus
AU3078997A (en) Improved processes for the reduction of imide ester functionality

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)